Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Although meningococcal disease caused by serogroup B remains an important public health concern, a licensed vaccine providing broad protection against this pathogen is not yet available. Advances in genomics have paved the way for the discovery of new vaccine candidates for inclusion into a multicomponent serogroup B vaccine. In this article, we will review recent advances in the development of these vaccines, focussing particularly on one of the 'next generation' MenB vaccines, 4CMenB.

Original publication

DOI

10.1586/erv.11.32

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

05/2011

Volume

10

Pages

575 - 588

Keywords

Antibodies, Bacterial, Antigens, Bacterial, Blood Bactericidal Activity, Cell-Derived Microparticles, Humans, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, Recombinant Proteins, Serum Bactericidal Antibody Assay